In clinical trials, inhibitory therapeutic targeting of the CCL2 and CCL22 axes were often unfavorable for patients61,85,89, reinforcing an overall anti-tumorigenic effect of CCL2 and CCL22 at least in certain tumor settings94. This evidence concerns the gene CCL22 and neoplasm.